DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Osimertinib In EGFR Mutant Lung Cancer

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Osimertinib

First Posted Date: 2018-07-13

Last Posted Date: 2025-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03586453

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Venetoclax
Drug: Obinutuzumab
Drug: Acalabrutinib

First Posted Date: 2018-07-10

Last Posted Date: 2024-07-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 72

Registration Number: NCT03580928

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States

and more 1 locations

The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients

Not Applicable

Completed

Conditions: Gastro Intestinal Cancer

Interventions: Other: Psychoeducational

First Posted Date: 2018-07-03

Last Posted Date: 2020-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT03576872

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Sexual Health and Rehabilitation After Ovarian Suppression Treatment

Not Applicable

Completed

Conditions: Ovarian Suppression Treatment
Breast Cancer Survivors
Sexual Function Disturbances

Interventions: Behavioral: Group Session
Behavioral: Telephone Booster

First Posted Date: 2018-06-28

Last Posted Date: 2021-11-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03571841

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Mathematical Model-Adapted Radiation In Glioblastoma

Not Applicable

Completed

Conditions: Recurrent Glioblastoma

Interventions: Radiation: Mathematical Model-Adapted Radiation Fractionation Schedule

First Posted Date: 2018-06-15

Last Posted Date: 2023-10-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT03557372

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Richter Syndrome

Interventions: Drug: Duvelisib
Drug: Venetoclax

First Posted Date: 2018-05-23

Last Posted Date: 2025-01-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 67

Registration Number: NCT03534323

Locations: 🇺🇸
Northern Light Eastern Maine Medical Center, Brewer, Maine, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 4 locations

Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes

Completed

Conditions: BK Virus Infection

Interventions: Other: Symptom index questionnaire
Diagnostic Test: BK polyomavirus PCR
Other: quality of life questionnaires

First Posted Date: 2018-05-22

Last Posted Date: 2024-05-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03532971

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Other: Placebo
Drug: Paricalcitol

First Posted Date: 2018-05-11

Last Posted Date: 2025-03-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT03520790

Locations: 🇺🇸
Penn Medicine, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Not Applicable

Completed

Conditions: Cancer
Chemotherapy-induced Peripheral Neuropathy

Interventions: Behavioral: CIPN Assessment and Management Algorithm

First Posted Date: 2018-05-02

Last Posted Date: 2022-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 226

Registration Number: NCT03514680

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

Not Applicable

Terminated

Conditions: Atypical Ductal Hyperplasia

Interventions: Device: Contrast enhanced mammography

First Posted Date: 2018-04-23

Last Posted Date: 2020-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03505372

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy